Physician profile
Thomas S Edwards
NPI 1316907157
$1,130.03
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $192 · 2021: $39.70 · 2022: $630 · 2023: $44.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.99 | 2019-2022 | |
| Lilly USA, LLC | $137.22 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $87.14 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $84.58 | 2022 | |
| Amgen INC. | $84.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.84 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $63.55 | 2022-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $42.03 | 2019-2022 | |
| Pfizer INC. | $41.79 | 2022 | |
| Merck Sharp & Dohme LLC | $33.94 | 2020-2021 | |
| Abbott Laboratories | $33.22 | 2020-2022 | |
| Abbvie INC. | $23.95 | 2022 | |
| Dexcom, INC. | $21.60 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.76 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.34 | 2022 | |
| Insulet Corporation | $16.93 | 2020 | |
| Boston Scientific Corporation | $16.18 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.